February 2nd, 2011 at 12:29am
Under General
Nizoral shampoo contains ketoconazole typically 1% or 2%. In some countries, 2% shampoo is consider “very strong” and requires a prescription. The use Nizoral twice a week usually keeps dandruff at bay. No need to use Nizoral shampoo daily because their main active ingredient, ketoconazole, binds to proteins in your hair for several days and keep attacking and killing the fungus that causes dandruff and infection.
If you use Nizoral hair loss I sugest you to use it everyday, it you will that it is to much for your scalp, use it at least 3 times per week. I never had any problem using it every day. When you use Nizoral for hair loss let it in your scalp for at least 5 minutes before clean it.
One of the well documented properties of Nizoral shampoo is its main active ingredient, ketoconazole, and its ability to fight baldness. In four scientific studies, ketoconazole 2% has proven to be at least as effective as minoxidil solution 2% in aid for hair growth.
It is assumed that ketoconazole works as an anti-androgen, the reduction of dihydrotestosterone (DHT) levels in the scalp. Nowadays, there is sufficient clinical evidence to confirm this hypothesis. Also the number of patients with hair loss experienced itching and swelling of the scalp caused by different solutions of minoxidil is very high and we hope Nizoral to help combat these negative side effects, usually with very good success rates. This allows them to continue treatment for hair loss, preventing inflammation of the scalp.
Consumer Comments Nizoral are numerous and very positive about treatment for dandruff and other fungal infections of the scalp concerns. Many who suffer from baldness or hair loss Nizoral included in their daily regimen because they believe in their ability to regenerate hair. However, it is almost impossible to find convincing evidence that Nizoral consumers have been helped by this product in the fight against baldness.
I suggest you read this paper about nizoral hair loss which has photos of before and after .
After two FDA-approved drugs (finasteride and minoxidil) for the treatment of androgenetic baldness, there is no other drug that has many independent studies (can be found on this site and check the veracity pubmed.gov) as ketoconazole (drug nizoral shampoo, nizoral cream, and foam extinguishing).
If you go back in time, and configuration needs this information, would be the first nizoral used to treat my hair loss, and then, according to the results, we would go adding other drugs (such as dutasteride or finasteride, minoxidil, etc). But for the good of its use, the number of published studies, the low cost and the scarcity of side effects, definitely ketoconazole (nizoral in any of their presentations, whether brand or generic) is the number one drug to treat baldness androgenetic.
By webmaster
January 5th, 2011 at 05:04pm
Under General
EFFECTIVENESS OF SERENOA REPENS ON ANDROGENETIC ALOPECIA
C. FASULO, A. LINGUITI, L. BOSCO, P. MORGANTI, R. A. SATRIANO
Aim: the aim of this double blinded study was to evaluate the activity performed by 3 different cosmetic formulations especially enriched with Serenoa Repens extract with a known quantity of total sterols on the hair growth and serbum secretion.
Method: 34 men and 28 women, aged 18-48 were divided into 3 groups using the products for 3 months.
The first group used all 3 products enriched with Serenoa repens extract, the second of all 3 products (placebo free of Serenoa repens extract), and the third group use used shampoo and lotion enriched with Serenoa repens extract, but dietary supplement placebo.
Results: the results showed a significant 35% hair increase both on number and mass, and a contemporary 67% decrease superficial sebum in the 1st group.
Group 3 revealed a hair increase of 20% with a contemporary decrease of deborrhea 35%. . Group 2 had no results.
Conclusions: this study confirms effectiveness of Serenoa repens extract on hair baldness such as androgenetic alopecia, especially when connected with 5 alpha reductase activity.
source :
hair transplant cost
By webmaster
April 29th, 2010 at 02:25am
Under General
BACKGROUND AND OBJECTIVES: The relationship between androgenetic alopecia and cardiovascular disease has been studied by some authors in the past, although the results of epidemiological studies have been variable. The objective of this study was to determine the prevalence of metabolic syndrome and carotid arteriosclerosis in patients with early-onset androgenetic alopecia. PATIENTS AND METHODS: Seventy men were studied, 35 with diagnosis of early-onset (before 35 years of age) androgenetic alopecia and 35 control subjects who consulted for other skin conditions. In both groups, the criteria for metabolic syndrome according to the Adult Treatment Panel-III were studied (obesity, triglycerides, high-density lipoprotein cholesterol, systolic and diastolic blood pressure, and blood glucose), presence of atheromatous plaques, and carotid intima-media thickness using Doppler ultrasonography. Other cardiovascular risk factors, hormones, and acute-phase reactants were also analyzed. RESULTS: Criteria for metabolic syndrome were met by 57.1% of the patients with androgenetic alopecia compared to 14.3% of the controls (P<0001). Thirty-four percent of the patients with androgenetic alopecia had atheromatous plaques compared to 8.6% of the controls (P=.018). In an independent correlation analysis, abdominal obesity, systolic blood pressure, triglycerides, and blood glucose levels were significantly greater among patients with androgenetic alopecia. Testosterone and sex hormone binding globulin levels were similar in the 2 groups whereas insulin and aldosterone levels were higher in patients with androgenetic alopecia (P<05). CONCLUSIONS: The high frequency of metabolic syndrome and carotid atheromatous plaques in patients with androgenetic alopecia suggests cardiovascular screening should be done to enable early detection of individuals at risk and initiation of preventive treatment before cardiovascular disease becomes established.
Arias-Santiago S, Gutiérrez-Salmerón MT, Castellote-Caballero L, Buendía-Eisman A, Naranjo-Sintes R.
Servicio de Dermatología, Hospital Clínico San Cecilio, Granada, España. salvadorarias@hotmail.es
Actas Dermosifiliogr. 2010 Apr;101(3):248-56.
By webmaster
April 18th, 2010 at 06:03pm
Under General
Three weeks of creatine monohydrate supplementation affects dihydrotestosterone to testosterone ratio in college-aged rugby players.
OBJECTIVE: This study investigated resting concentrations of selected androgens after 3 weeks of creatine supplementation in male rugby players. It was hypothesized that the ratio of dihydrotestosterone (DHT, a biologically more active androgen) to testosterone (T) would change with creatine supplementation. DESIGN: Double-blind placebo-controlled crossover study with a 6-week washout period. SETTING: Rugby Institute in South Africa. PARTICIPANTS: College-aged rugby players (n = 20) volunteered for the study, which took place during the competitive season. INTERVENTIONS: Subjects loaded with creatine (25 g/day creatine with 25 g/day glucose) or placebo (50 g/day glucose) for 7 days followed by 14 days of maintenance (5 g/day creatine with 25 g/day glucose or 30 g/day glucose placebo). MAIN OUTCOME MEASURES: Serum T and DHT were measured and ratio calculated at baseline and after 7 days and 21 days of creatine supplementation (or placebo). Body composition measurements were taken at each time point. RESULTS: After 7 days of creatine loading, or a further 14 days of creatine maintenance dose, serum T levels did not change. However, levels of DHT increased by 56% after 7 days of creatine loading and remained 40% above baseline after 14 days maintenance (P < 0.001). The ratio of DHT:T also increased by 36% after 7 days creatine supplementation and remained elevated by 22% after the maintenance dose (P < 0.01). CONCLUSIONS: Creatine supplementation may, in part, act through an increased rate of conversion of T to DHT. Further investigation is warranted as a result of the high frequency of individuals using creatine supplementation and the long-term safety of alterations in circulating androgen composition. STATEMENT OF CLINICAL RELEVANCE: Although creatine is a widely used ergogenic aid, the mechanisms of action are incompletely understood, particularly in relation to dihydrotestosterone, and therefore the long-term clinical safety cannot be guaranteed.
van der Merwe J, Brooks NE, Myburgh KH.
Department of Clin J Sport Med. 2009 Sep;19(5):399-404.
By webmaster
Previous Posts